Highest-materiality recent filing
10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform
Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.
10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M
Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).
Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.
10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M
Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.
10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M
Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).
10x Genomics settles patent litigation with Bruker; to receive $68M upfront plus royalties
Settled all patent litigation with Bruker (formerly NanoString) regarding spatial biology platforms; all claims dismissed with prejudice.
10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance
Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.
10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat
Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).
10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M
Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.
10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%
Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).
Q2 revenue $153.1M, +4% YoY; net loss $37.9M vs $62.4M loss in prior year.
10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed
Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.
10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth
Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance
James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.
10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%
Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.
On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors
Justin J. McAnear, who on August 6, 2024 notified the Company of his intention to resign and who will continue to provide transition services as an employee of the Company through August 30, 2024.
On August 8, 2024, the Company announced that Adam S. Taich will be joining the Company as its Chief Financial Officer, effective August 12, 2024, replacing Justin J. McAnear
On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.
appointed Alan V. Mateo to the Board of Directors as a Class II director effective immediately
On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings